DanNuo Pharmaceutical (Suzhou) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, aiming for a main board IPO. Founded in 2013, the company focuses on developing treatments for bacterial infections and bacterial metabolic diseases. It has entered into a commercialization agreement with Yuanda Life Sciences, potentially valued at up to 775 million yuan, and counts prominent investors like WuXi AppTec, Northern Light Venture Capital, and Gaotejia Investment among its shareholders.
However, a closer look at its financials, ownership structure, operational model, and partnership details reveals several challenges. The company has accumulated losses of 376 million yuan over three years, with R&D spending shrinking annually, indicating reliance on external funding. Although its core product secured a 775 million yuan partnership, the agreement includes performance-based clauses that could jeopardize the deal if regulatory or reimbursement milestones are not met. Additionally, the founder holds only a 3.16% stake, raising concerns about control stability.
Over the past three years, DanNuo has reported net losses of 192 million yuan, 146 million yuan, and 116 million yuan, totaling 376 million yuan. The company has yet to generate any product revenue. Notably, R&D expenses have declined significantly, falling from 108 million yuan to 69.84 million yuan and then to 46.4 million yuan, with their share of total operating costs dropping from 84.8% to 56.2%.
To sustain operations, DanNuo has repeatedly turned to financing, but these rounds came with redemption clauses. As a result, redemption liabilities climbed to 767 million yuan, 932 million yuan, and 1.05 billion yuan at various points. Although special rights tied to these liabilities were canceled in May 2025, eliminating redemption liabilities from the books, the company remains dependent on external capital.
Operating cash flow stayed negative throughout the reporting period, at -98.12 million yuan, -48.6 million yuan, and -69.45 million yuan. By the end of March 2025, cash on hand was just 146 million yuan, though it increased to 222 million yuan after E2 and E3 financing rounds in the first three quarters of 2025.
DanNuo’s pipeline includes seven innovative projects targeting bacterial infections and related metabolic diseases. One asset, Lifotonazole, is near commercialization, two are in Phase II trials, one has IND approval, and three are in preclinical stages. Advancing these programs will likely require higher R&D expenditures, intensifying financial pressure given the lack of self-sustaining revenue.
Commercial prospects remain uncertain. Helicobacter pylori infection represents a significant public health burden, classified as a Group I carcinogen by the WHO and linked to about 80% of gastric cancer cases. In China, 621.1 million people are infected, with global infections reaching 4.081 billion. Current treatments face high drug resistance rates—40.8% to clarithromycin, 68.2% to metronidazole, and 35.1% to levofloxacin—with 85.1% of patients resistant to at least one recommended antibiotic.
Lifotonazole, DanNuo’s lead candidate, combines rifamycin and nitroimidazole pharmacophores to inhibit bacterial RNA polymerase and nitroreductase simultaneously. In a Phase III head-to-head trial, it demonstrated over 90% eradication rates, superior efficacy in multidrug-resistant populations, and better safety than bismuth-based quadruple therapy. However, changing entrenched prescription habits will require substantial medical education and marketing efforts—a challenge for a company with no commercial experience.
To address this, DanNuo partnered with Yuanda Life Sciences for exclusive commercialization rights in Greater China (excluding Taiwan). The deal includes up to 775 million yuan in payments: a 25 million yuan upfront fee, 65 million yuan in milestone payments tied to regulatory approval and inclusion in China’s national reimbursement drug list (NRDL), up to 71 million yuan in sales-based promotion fees, and up to 20 million yuan in performance bonuses. DanNuo will pay promotion service fees starting at 75% and gradually reducing to 65%.
Critically, the agreement contains performance clauses. If Lifotonazole fails to secure Chinese marketing approval for H. pylori infection by December 31, 2026, Yuanda can terminate the deal and demand repayment of the 25 million yuan milestone payment. If the drug is not included in the 2027 NRDL, Yuanda may renegotiate terms or terminate the agreement. Without NRDL coverage, market penetration would slow, and DanNuo—lacking its own sales force—could be forced to concede more favorable terms in any renegotiation.
Corporate governance is another concern. Founder Ma Zhenkun established DanNuo in Suzhou Industrial Park in 2013, but his stake was diluted to 13.78% early on when former employer Cumbre acquired 80.10% of DanNuo Cayman via patent and technology licensing. After multiple funding rounds, Ma’s direct holding is just 3.16%, with total voting control around 13.61% including an employee incentive platform. Of the nine board members, Ma appoints only two, with the rest named by other investors. This weak control could complicate major strategic decisions, especially if short-term performance pressures conflict with long-term R&D goals.
Comments